Marker Therapeutics, Inc.

Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.

MRKR | US

Overview

Corporate Details

ISIN(s):: US57055L1070 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://markertherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation, non-genetically modified T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology, Multi-Antigen Recognizing (MAR) T cells, expands a patient's natural T cells to recognize and eliminate tumors expressing multiple antigens. This approach aims to provide durable anti-tumor responses with a favorable safety profile compared to genetically engineered cell therapies. The technology was developed at Baylor College of Medicine. Its lead product candidate, MT-601, is being evaluated in a Phase 1 study for lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Marker Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marker Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Marker Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
NIPPON CHEMIPHAR CO., LTD. Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.	Japan	4539
Nippon Shinyaku Co.,Ltd. Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.	Japan	4516
Nkarta, Inc. Developing off-the-shelf NK cell therapies for cancer and autoimmune diseases.	United States of America	NKTX
NKMAX Co., Ltd. Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.	South Korea	182400
NLS Pharmaceutics Ltd. Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.	United States of America	NLSP
NovaBay Pharmaceuticals, Inc. Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.	United States of America	NBY
Novacyt Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.	France	ALNOV
Novartis AG Develops and markets innovative medicines globally using advanced science and technology.	Switzerland	NOVN
NOVAVAX INC Develops and commercializes nanoparticle vaccines for serious infectious diseases.	United States of America	NVAX
NovMetaPharma Co., Ltd. Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.	South Korea	229500